Immunotherapy
Immunotherapy is offering exciting new treatments for many types of cancer. It works by revving up the immune system and can have various side effects in different patients. Read More ›
A new study found that untreated patients with advanced non–small-cell lung cancer (NSCLC) who received a combination of 2 immunotherapy drugs—nivolumab (Opdivo) and ipilimumab (Yervoy)—had increased overall survival (OS) compared with patients who received chemotherapy. In short, the patients on the immunotherapy drug combination lived longer. Read More ›
When first seen by a physician, 25% to 30% of patients with non–small-cell lung cancer (NSCLC) already have locally advanced disease. Standard treatment for these patients has been platinum-based chemotherapy plus radiation (chemoradiation), which achieved a median progression-free survival (PFS) of approximately 8 months and a 5-year overall survival (OS) rate of 15% to 30%. Recent developments in immunotherapy have provided significant advances in the treatment of NSCLC. Read More ›
Recently, Tecentriq became the first immunotherapy to be approved for the treatment of patients with metastatic triple-negative breast cancer, a particularly difficult type of breast cancer. Read More ›
Triple-negative breast cancer is an aggressive type of cancer that usually has a high rate of disease recurrence (returning) within the first 5 years after diagnosis. Read More ›
The immune system attacks foreign substances by making large numbers of antibodies. These are proteins that attach to a specific protein on the cell called an antigen. Read More ›
In March 2019, the FDA approved Tecentriq (atezolizumab), a PD-L1 inhibitor, in combination with Abraxane (paclitaxel protein-bound), for use in adults with locally advanced or metastatic triple-negative breast cancer whose tumors cannot be removed by surgery and express PD-L1, as identified by an FDA-approved test. This is the first FDA-approved immunotherapy for patients with advanced or metastatic triple-negative breast cancer. Read More ›
By Dana Taylor
Triple-negative breast cancer has few treatment options. Promising results from recent clinical trials of immunotherapy combined with chemotherapy in patients with metastatic disease may soon change the way this aggressive cancer is treated. Just after this article was written, the FDA approved this combination for patients with triple-negative breast cancer. Read More ›
Dr Morganna Freeman explains the difference between immunotherapies and targeted therapies in plain language for patients to easily understand. Read More ›